| Autor: |
T, Basturk, A, Unsal, T, Ulas, Y, Koc, T, Sakaci, E, Ahbap, F, Borlu |
| Rok vydání: |
2012 |
| Předmět: |
|
| Zdroj: |
European review for medical and pharmacological sciences. 16(11) |
| ISSN: |
1128-3602 |
| Popis: |
The aim of the study was to investigate the effects of rosiglitazone treatment on insulin resistance (IR) and tumor necrosis factor-alpha (TNF-alpha) levels in non-diabetic chronic kidney disease (CKD) patients with IR.Thirty non-diabetic CKD patients with IR were enrolled in the study. Patients were grouped into two: group 1 (n = 15) received rosiglitazone 4 mg tablet for 3 months and patients who did not receive rosiglitazone treatment constituted the group 2 (n = 15). Baseline and after rosiglitazone treatment, homeostatis model assessment-insulin resistance (HOMA-IR) and TNF-alpha levels were measured.There were no statistical differences in gender, age, HOMA-IR and TNF-alpha levels among group 1 and group 2 (p0.05 for all). Compared to baseline in group 1, significant differences were found in HOMA-IR and TNF-alpha levels after 3 months (p = 0.023; p = 0.001, respectively).Our study indicates that, rosiglitazone treatment improves the IR and decreases TNF-alpha levels in non-diabetic patients CKD with IR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
